Navigation Links
Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
Date:11/5/2008

SEATTLE, Nov. 5 /PRNewswire-FirstCall/ -- On Friday, November 7, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq: CTIC) (MTA: CTIC) management team will host a quarterly conference call to discuss the Company's 2008 third quarter achievements and financial results.

Conference Call Numbers

Friday, November 7

8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time

1-877-835-3299 (US Participants)

1-303-262-2078 (International)

Call-back numbers for post-listening available at 11:30 a.m. Eastern:

1-800-405-2236 (US Participants)

1-303-590-3000 (International)

Passcode: 11121525#

Live audio webcast at http://www.celltherapeutics.com will be archived for post listening approximately two hours after call ends.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

F: 206.272.4434

E: media@ctiseattle.com

http://www.celltherapeutics.com/press_room

Investors Contact:

Ed Bell

T: 206.282.7100

Lindsey Jesch Logan

T: 206.272.4347

F: 206.272.4434

E: invest@ctiseattle.com

http://www.celltherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
2. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
3. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
4. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
6. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
7. Cell Therapeutics, Inc. Announces Reverse Stock Split
8. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
9. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
10. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
11. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... TRIANGLE PARK, N.C., Feb. 22, 2017  United Therapeutics ... its financial results for the fourth quarter and ... 2016 financial results reflect continued growth as net ... million," said Martine Rothblatt, Ph.D., United Therapeutics, Chairman ... our ability to develop and advance our growing ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... to build connected digital health applications, announced a partnership with Redox, a leader ... seamlessly connect to many clinical systems while keeping data secure in the cloud. ...
(Date:2/21/2017)... ... February 21, 2017 , ... Cancer diagnostics ... has joined its executive team to lead the development and commercialization of its ... help improve the diagnosis and treatment of cancer. The CIDT addresses the need ...
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... ... its GMP cell therapy manufacturing facility at its headquarters laboratory in Poway, California. ... and utilizing the experience of both in-house personnel and consultants, VetStem constructed and ...
Breaking Biology Technology:
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
(Date:2/8/2017)... -- Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion ... at a compound annual growth rate (CAGR) of 24.0% through ... markets for synthetic biology. - Analyses of global market trends, ... compound annual growth rates (CAGRs) through 2021. - Coverage of ...
Breaking Biology News(10 mins):